Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ...
All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Takeda Pharmaceutical Co. (TAK) Upgraded to Buy: What Does It Mean for the Stock?
Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Japan's Takeda partners with India's Biological E. to boost dengue vaccine production
Japan's Takeda Pharmaceutical will scale up production of its dengue vaccine Qdenga through a partnership with Indian vaccines maker Biological E., the companies said on Tuesday.
US FDA approves Takeda's therapy for allergic inflammation in esophagus
Drugmaker Takeda said on Monday the U.S. Food and Drug Administration has approved its therapy for a type of allergic inflammation of the esophagus, making it the first oral treatment for the condi...
One Ultra-Cheap High-Yield Dividend Stock to Buy
Takeda Pharmaceutical is one of the top pharma companies in the world. It has a broad mix of products in its portfolio, which can provide investors with some stability.
US FDA approves Takeda's blood disorder therapy
The U.S. Food and Drug Administration on Thursday approved Takeda Pharmaceutical's therapy to treat a rare genetic blood disorder in adult and pediatric patients.
Takeda says FDA approves its treatment for colorectal cancer
Pharmaceutical company Takeda 4502, +0.29% said Wednesday that the U.S. Food and Drug Administration approved Fruzaqla as a treatment for certain patients with colorectal cancer.
Takeda Pharmaceutical Company Limited (TAK) Q2 2023 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2023 Earnings Conference Call October 26, 2023 6:00 AM ET Company Participants Christopher O'Reilly - Head of Investor Relations Christophe Webe...
Japan's Takeda slashes full-year profit forecast on drug pipeline impairments
Japan's biggest drugmaker Takeda Pharmaceutical on Thursday slashed its full-year profit forecast by 36% as it contends with disappointments in its development pipeline and the loss of patent prote...
Takeda: Why I'm Staying Bearish On This Generic Drug Dividend Play
High yields may seem attractive, however, homework can go a long way. Takeda's Phase 3 ADMIRE CD II study & Phase 3 EXCLAIM-2 trial both failed to meet key endpoints, thus impacting the company's F...
Takeda trial for Crohn's Perianal Fistulas treatment misses primary endpoint
Takeda 4502, -0.33% said Tuesday its trial of darvadstrocel in the treatment of complex Crohn's Perianal Fistulas didn't meet its primary endpoint based on topline data.
Takeda's dengue vaccine gets WHO group's recommendation
American depositary receipts of Takeda Pharmaceutical Co. 4502, -1.79% TAK, -2.16% rose more than 1% in the extended session Tuesday after the Japan-based company said its dengue vaccine got the re...
Takeda announces voluntary withdrawal of lung cancer therapy
Takeda Pharmaceutical said on Monday it would be working with the U.S. health regulator towards a voluntary withdrawal of its lung cancer therapy in the country, after it failed to meet the main go...
Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse
Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.
Related Companies